GT200300142A - Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos - Google Patents

Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos

Info

Publication number
GT200300142A
GT200300142A GT200300142A GT200300142A GT200300142A GT 200300142 A GT200300142 A GT 200300142A GT 200300142 A GT200300142 A GT 200300142A GT 200300142 A GT200300142 A GT 200300142A GT 200300142 A GT200300142 A GT 200300142A
Authority
GT
Guatemala
Prior art keywords
vpac2
hypofisary
cyclass
pacap
adenylate
Prior art date
Application number
GT200300142A
Other languages
English (en)
Inventor
Wayne A Froland
Drew N Kelner
Michael L Dumas
Clark Pan
James Whelan
Yu-Chang John Wang
Wei Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300142A publication Critical patent/GT200300142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVOS PEPTIDOS QUE FUNCIONAN IN VIVO COMO AGONISTAS DEL RECEPTOR VPAC2 Y SE DEMUESTRA QUE ESTOS POLIPEPTIDOS SECRETAGOGOS DE LA INSULINA REDUCEN MAS LA GLUCOSA SANGUINEA QUE LOS CONTROLES, LUEGO DE LA PROVOCACION CON GLUCOSA, POR LO QUE SON DE UTILIDAD EN PACIENTES CON SECRECION REDUCIDA DE INSULINA, PARTICULARMENTE PARA LA DIABETES TIPO 2.
GT200300142A 2002-07-12 2003-07-11 Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos GT200300142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39573802P 2002-07-12 2002-07-12

Publications (1)

Publication Number Publication Date
GT200300142A true GT200300142A (es) 2004-03-17

Family

ID=30115918

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300142A GT200300142A (es) 2002-07-12 2003-07-11 Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos

Country Status (20)

Country Link
US (2) US7378494B2 (es)
EP (1) EP1578358A2 (es)
JP (1) JP2006506969A (es)
CN (1) CN101405298A (es)
AR (1) AR040548A1 (es)
AU (1) AU2003267990A1 (es)
BR (1) BR0312621A (es)
CA (1) CA2491279A1 (es)
DO (1) DOP2003000669A (es)
GT (1) GT200300142A (es)
HN (1) HN2003000217A (es)
IL (1) IL165499A (es)
MX (1) MXPA04012305A (es)
PE (1) PE20040677A1 (es)
PL (1) PL377025A1 (es)
RU (1) RU2360922C2 (es)
TW (1) TW200409641A (es)
UY (1) UY27893A1 (es)
WO (1) WO2004006839A2 (es)
ZA (1) ZA200501118B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301431D0 (sv) * 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
BRPI0507177A (pt) * 2004-01-27 2007-06-26 Bayer Pharmaceuticals Corp agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso
DE602005005476T2 (de) * 2004-05-21 2009-03-05 Eli Lilly And Co., Indianapolis Selektive peptidische agonisten des vpac2-rezeptors
ATE412010T1 (de) * 2004-05-21 2008-11-15 Lilly Co Eli Selektive peptidische agonisten des vpac2- rezeptors
CA3090413C (en) 2004-06-04 2023-10-10 Abbott Diabetes Care Inc. Glucose monitoring and graphical representations in a data management system
CN101001639A (zh) * 2004-06-12 2007-07-18 拜尔药品公司 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
WO2006023359A2 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
WO2006042152A2 (en) 2004-10-08 2006-04-20 Forbes Medi-Tech (Research) Inc. Vasoactive intestinal polypeptide pharmaceuticals
US7595294B2 (en) 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
US20070293429A1 (en) * 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US20080214440A1 (en) * 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US20060159737A1 (en) * 2004-11-19 2006-07-20 Steffen Panzner Pharmaceutical compositions for local administration
DE602005014672D1 (de) * 2004-12-21 2009-07-09 Lubrizol Ltd Zusammensetzungen
ES2365410T3 (es) * 2005-04-08 2011-10-04 Amylin Pharmaceuticals, Inc. Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico.
EP1896048A4 (en) * 2005-05-06 2010-11-03 Bayer Pharmaceuticals Corp PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE
US20080194482A1 (en) * 2005-08-11 2008-08-14 Jorge Alsina-Fernandez Selective Apac2 Receptor Peptide Agonists
EP1942941A1 (en) * 2005-10-26 2008-07-16 Eli Lilly And Company Selective vpac2 receptor peptide agonists
AU2007220775A1 (en) * 2006-02-28 2007-09-07 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
WO2010021752A1 (en) * 2008-08-21 2010-02-25 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
EP3177309A4 (en) * 2014-08-06 2018-08-15 Vascular Biosciences Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same
WO2016168760A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
WO2017181031A2 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) * 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use

Also Published As

Publication number Publication date
US20090258826A1 (en) 2009-10-15
DOP2003000669A (es) 2004-01-31
EP1578358A2 (en) 2005-09-28
WO2004006839A2 (en) 2004-01-22
RU2360922C2 (ru) 2009-07-10
PE20040677A1 (es) 2004-10-29
ZA200501118B (en) 2006-08-30
BR0312621A (pt) 2005-12-06
US20040058870A1 (en) 2004-03-25
MXPA04012305A (es) 2005-02-25
IL165499A (en) 2010-12-30
US7378494B2 (en) 2008-05-27
RU2005103396A (ru) 2005-09-20
JP2006506969A (ja) 2006-03-02
AU2003267990A1 (en) 2004-02-02
HN2003000217A (es) 2004-07-26
UY27893A1 (es) 2003-12-31
CN101405298A (zh) 2009-04-08
TW200409641A (en) 2004-06-16
PL377025A1 (pl) 2006-01-23
AR040548A1 (es) 2005-04-13
CA2491279A1 (en) 2004-01-22
IL165499A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
GT200300142A (es) Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
DOP2002000475A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacológico
AR061203A1 (es) Moduladores del receptor glp-1 modificados en la terminal n
SV2002000184A (es) Agonistas del receptor 3 (r3) del peptido activador de la ciclasa adenilato de la pituitaria (pacap) y sus metodos farmacologicos de uso, ref. msb-7272 cip2-sv
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
CL2017001760A1 (es) Compuestos co-agonistas de gip y glp-1
CY1116917T1 (el) Αναλογα οξυντομοντουλινης
WO2006121860A3 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
AR053495A1 (es) Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
DK0699686T3 (da) Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid
UY26689A1 (es) Activadores de glucocinasa que contienen hidantoina
TR201903610T4 (tr) Alfa-melanosit uyarici hormonlarin peptid analoglari.
ECSP12012181A (es) Nuevos péptidos y métodos para su preparación y uso
PE20071141A1 (es) Derivados de metastina
DE69942307D1 (de) N-terminal veränderte glp-1 abkömmlinge
PE20211417A1 (es) Analogos novedosos de glp-1
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
AR036449A1 (es) Metodos para sintetizar conjugados polipeptido insulinico-oligomero y conjugados polipeptido proinsulinico-oligomero y metodos para sintetizar dichos conjugados
AR053263A1 (es) Agonistas del receptor (vpac2) de peptido activador de adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologico
Dekan et al. Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin
ECSP066793A (es)
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
DK1704234T3 (da) Fremstilling af glucagon-lignende peptid 2 og analoger
ECSP003683A (es) Agonistas del receptor 3(r3) del peptido activador de la adenilato ciclasa de la pituitaria y sus metodos de uso farmacologico
CL2009000900A1 (es) Proteina de fusion que comprende la hormona liberadora de gonadotrofinas fusionada a una secuencia con capacidad inmunogenica con sitios de o-glicosilacion; secuencia de adn que la codifica; procedimiento de produccion; vacuna que las comprende; y su uso para inmunocastracion de mamiferos.